SG3 Management’s Dynavax Technologies DVAX Stock Holding History

SG3 Management’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,000	Closed	-$197K	–	1102
2021 Q1	$197K	Buy	+20,000	New	+$165K	﹤0.01%	968

Other funds holding DVAX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SG3 Management's DVAX Position: Q2 2021 in Review

SG3 Management sold out of Dynavax Technologies (DVAX) in Q2 2021, closing a stake of 20,000 shares — an estimated $197K sold.

SG3 Management first reported a position in DVAX in Q4 2016 and held it in 3 quarters. The position peaked at $197K in Q1 2021. 154 funds tracked by Wall St. Rank hold DVAX as of Q2 2021.

SG3 Management reported no remaining Dynavax Technologies position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 20,000 Dynavax Technologies shares in Q2 2021, an estimated $197K.
SG3 Management first reported a position in Dynavax Technologies in Q4 2016 and held it in 3 quarters.
SG3 Management's Dynavax Technologies position peaked at $197K in Q1 2021.
154 funds tracked by Wall St. Rank held Dynavax Technologies as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.